Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa

Geneva-based Relief Therapeutics Holding SA has announced favorable final results from its RLF-TD011 clinical trial targeting epidermolysis bullosa (EB), a rare genetic disorder causing fragile skin and chronic wounds. The trial assessed the impact of RLF-TD011 on the microbiome diversity of EB wounds, particularly in severe disease forms.

The study successfully reached its primary goal, noting a significant 24% reduction in S. aureus abundance, correlating with reduced wound size. At the study's conclusion, 78% of wounds showed closure, alongside improved microbiome diversity. These benefits persisted through a four-week observation.

Prof. Amy Paller highlighted the spray's antimicrobial role in wound care, while Relief's Chief Scientific Officer noted the potential for advancing treatment options. The findings will guide future U.S. FDA consultations.